Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Share News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.475
Bid: 1.45
Ask: 1.50
Change: -0.025 (-1.67%)
Spread: 0.05 (3.448%)
Open: 1.50
High: 1.50
Low: 1.475
Prev. Close: 1.50
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: UK NICE backs Genedrive test; Corero renews deal

Wed, 03rd Apr 2024 10:47

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Genedrive PLC, up 57% at 5.90 pence, 12-month range 2.56p-34.90p. The molecular diagnostics company announces that the UK's National Institute for Health & Care Excellence has recommended in draft guidance that Genedrive's CYP2C19-ID test should be used as the point-of-care test of choice for ischemic stroke and transient ischaemic attack patients. Chief Executive Officer James Cheek comments: "We are delighted to receive this recommendation from NICE for our CYP2C19 point of care pharmacogenetic test. The NHS has done significant work on both strokes and mini strokes, with campaigns for face, arms, speech and time, and promoting changing lifestyles to prevent a stroke. This guidance is just the next step in stroke management, ensuring that if you have a stroke, specifically related to a disruption of the blood flow, that the medicine given has a positive effect....With MT-RNR1 getting a NICE EVA conditional recommendation last year, further funding applied for to achieve a full recommendation this year, a strategy in place to achieve US Food & Drug Administration approval and sales being realised from new customers in 2024 we feel there is growing momentum within the group's POC pharmacogenetic testing strategy."

----------

Corero Network Security PLC, up 15% at 10.36p, 12-month range 5.50p-10.65p. The cybersecurity provider specialising in distributed denial-of-service protection solutions wins a contract renewal worth over USD2 million over three years with an unnamed US-based software-as-a-service provider, expanding its partnership and marking one of Corero's "largest" single transactions to date. Corero says the deal reinforces its strong customer retention track record, while "significantly" enhancing the customer's distributed denial-of-service protection infrastructure. This ensure the "security and service availability of the SaaS provider's worldwide operations and reinforcing its resilience against the burgeoning range of cyberthreats". Corero Chief Executive Officer Carl Herberger comments: "We are committed to providing cutting-edge, reliable DDoS protection solutions to support our customers' growth and operational security and will continue to explore new business and mandate expansion opportunities as we aim to both broaden and strengthen our client portfolio."

----------

AIM - LOSERS

----------

Peel Hunt Ltd, down 5.1% at 120.00p, 12-month range 78.00p-142.00p. The investment bank expects a full-year loss as increasing costs offset a modest rise in revenue. In a trading statement for the year to March 31, Peel Hunt says revenue is expected to be consistent with market expectations at around GBP85.5 million, up 3.9% from GBP82.3 million last year. This growth comes despite equity capital markets "remaining challenging" throughout the financial year. Looking ahead, the firm expects market trading volumes to remain low until there are meaningful signs of recovery in the UK economy and fund outflows reverse. It notes whilst initial public offering activity in the UK remains muted, there has been more activity in Europe and sentiment towards IPOs is improving in the UK, with investors increasingly willing to engage in relation to high quality companies.

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Apr 2018 12:56

Genedrive To Unveil Hepatitis C ID Kit In Singapore Exhibition

LONDON (Alliance News) - Molecular diagnostics firm Genedrive PLC said Tuesday it is to premiere its hepatitis C ID kit in the Asia Pacific at an in will

Read more
20 Mar 2018 13:59

Genedrive Confident For Future As Interim Loss Narrows On Lower Costs

LONDON (Alliance News) - Genedrive PLC said on Tuesday that its pretax loss narrowed in the first half of the financial year as financing costs reduced for six months to the a

Read more
13 Mar 2018 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 14 March PrudentialFull Year ResultsDignityFull Year MacdonaldHalf 15

Read more
27 Jan 2017 09:42

Genedrive's revenues rise despite difficulties in India

(ShareCast News) - Genedrive, an AIM listed near patient molecular diagnostics diagnostics company, has progressed well in the second half despite difficulties faced with its Tuberculosis (TB) assay in India. Group revenues "significantly" rose to £2.8m for six months ended 31 December 2016, up f

Read more
16 Jan 2017 16:11

Genedrive supplies field test units to US DoD

(ShareCast News) - Manchester-based diagnostics company genedrive announced on Monday that it has supplied Genedrive units and assays to the United States Department of Defense for field trials, as part its $7.8m development programme for a handheld device to allow for the detection of biohazards su

Read more
17 Nov 2016 09:53

Genedrive Human Genotyping Test Gets EU Certification

Read more
11 Oct 2016 14:05

Genedrive's revenue rises while it re-focuses company

(ShareCast News) - AIM-listed molecular diagnostics company Genedrive's revenue grew as it re-focused to concentrate on its Genedrive platform, launched a new test in India and changed its name. For the year ended 30 June, the company, formerly Epistem, reported 12% growth in turnover to £5.1m, comp

Read more
11 Oct 2016 13:11

CORRECT: Genedrive Loss Widens As Product Sales Slow To Materialise

Read more
21 Sep 2016 08:43

Genedrive appoints Matthew Fowler CFO

(ShareCast News) - AIM-listed molecular diagnostic company Genedrive appointed Matthew Fowler as chief financial officer and a member of the board. He will start at a date to be confirmed shortly and will replace John Rylands who has been with company since 2002. Fowler joins Gendrive from Scapa Gr

Read more
2 Aug 2016 09:19

Genedrive Sees Strong Revenue Increase But Wider Annual Loss

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.